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K2HPO4  dipotassium hydrogen phosphate 
KCl  potassium chloride 
kDa Kilodalton 
KH2PO4  potassium dehydrogen phosphate 
L liter 
LAT latex agglutination test 
LFD  Lateral flow dipstick  
LM  light microscopy  
M molarity 
mA milliampere 
MAb   Monoclonal antibodies 
mg milligram 
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MgCl2  magnesium Chloride 
mL millilitre 
mm millimeter 
mM millimole 
mV millivolt  
MWCO molecular weights cut-off 
Na2CO3  sodium carbonate 
Na2HPO4  disodium hydrogen phosphate 
NaCL sodium chloride 
nAgB  native Antigen B 
NaHCO3 sodium bicarbonate 
NaN3 sodium azide  
NaOH sodium hydroxide 
NCM  nitrocellulose membrane 
ng nanogram 
(NH4)2SO4  ammonium sulphate 
NI-NTA nickel-nitrilotriacetic acid 
nm nanometers (wave length) 
NTDs  neglected tropical diseases 
OD  Optical density 
OI Optical intensity 
OIE  Office International des Epizooties (World Organization of 
Animal Health) 
PAIR puncture, aspiration, injection, and reaspiration 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
psi pound-force per square inch 
rAgB  recombinant antigen B 
ROC  Receiver operating characteristic 
RT  room temperature 
SDS  Sodium dodecyl sulfate  
SDS-PAGE sodium dodecyl sulphate polyacrylamide gel electrophoresis 
TBS  Tris buffered saline 
TBS-T  Tris buffered saline/0.05% Tween 
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TEMED N,N,N’,N’-tetramethylethylenediamine 
U Unit 
US Ultrasonography 
USM Univesiti Sains Malaysia 
V Volt 
v/v volume/volume 
v/w volume/weight 
WB Western blot 
WHO World Health Organization 
WHO-IWGE World Health Organization-Informal Working Group on 
Echinococcosis 
 
 
 
 
 
xxii 
 
PEMBANGUNAN DAN PENILAIAN UJIAN PENGESANAN ANTIGEN 
UNTUK PENYAKIT SISTA HIDATID 
 
 
ABSTRAK 
 
Penyakit sista hidatid (HCD) adalah penyakit parasit zoonotik yang boleh 
menjangkiti manusia dan haiwan. Ujian pengimejan dan pengesanan antibodi telah 
digunakan untuk mendiagnosis HCD, yang terdahulu tidak dapat membezakan antara 
sista hidatid dan patologi lain; manakala yang lain mungkin tidak dapat membezakan 
antara jangkitan lampau dan kini, dan mungkin juga tidak sesuai untuk menilai 
keberkesanan rawatan. Dalam hal ini, ujian pengesanan antigen dapat membantu 
menangani isu-isu di atas. Sebelum ini telah dilaporkan bahawa antigen sista hidatid 
dapat dikesan dalam pesakit HCD menggunakan pelbagai assai. Walau 
bagaimanapun keputusan yang dilaporkan tidak memuaskan, dengan kepekaan 
diagnostik yang berubah-ubah (25%-83%). Oleh itu, kajian ini bertujuan untuk 
membangunkan ujian pengesanan antigen untuk penyakit HCD. Satu panel sampel 
yang terdiri daripada serum pesakit HCD (n = 35), individu yang sihat (n = 38) dan 
pesakit yang dijangkiti parasit lain (n = 13) telah digunakan dalam kajian ini. Tiga 
jenis antigen E. granulosus disediakan iaitu cecair sista hidatid (HCF), antigen B 
natif (nAgB), dan antigen B rekombinan (rAgB). Antibodi poliklonal terhadap setiap 
antigen dihasilkan dalam arnab, diikuti dengan penulenan antibodi IgG. Seterusnya, 
sebahagian daripada IgG tersebut dilabelkan dengan enzim ‘horseradish peroxidase’ 
(HRP). Dengan menggunakan tiga jenis IgG dan tiga jenis antibodi terkonjugat 
dengan HRP, pelbagai gabungan sandwic ELISA telah diuji. Gabungan ELISA yang 
terbaik telah dioptimumkan lagi dan dinilai menggunakan panel sampel serum. 
Seterusnya, sebahagian daripada IgG yang ditulenkan telah konjugatkan dengan 
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nanopartikel emas untuk pembangunan dipstik aliran sisi (LFD). Dipstik aliran sisi 
dititis dengan tiga IgG yang berlainan, dan assai LFD menggunakan pelbagai 
kombinasi antibodi tangkapan dan pengesan diuji. Gabungan asai LFD terbaik 
kemudiannya dioptimumkan dan dinilai secara kualitatif (secara visual) dan secara 
kuantitatif menggunakan alat pembaca aliran sisi. Hasil keputusan menunjukkan 
bahawa gabungan ELISA yang menggunakan IgG anti-HCF sebagai antibodi 
tangkapan, dan anti-nAgB IgG-HRP sebagai antibodi pengesan mempamerkan 
isyarat yang terbaik di antara semua kombinasi lain. Walau bagaimanapun, ujian 
selanjutnya menunjukkan bahawa nilai diagnostiknya rendah. Sementara itu, ujian 
gabungan LFD dipstik yang dititiskan dengan anti-nAgB IgG dan nanopartikel emas 
yang terkonjugat dengan anti-HCF IgG sebagai pengesan adalah yang terbaik. 
Selanjutnya, ujian LFA telah menunjukkan 77.14% sensitiviti diagnostik dan 82.35%  
spesifisiti diagnostik. AUC daripada ujian LFD ialah 0.849, ini menunjukkan 
ketepatan diagnostik yang baik. Kesimpulannya, pengesanan antigen ujian LFD 
menunjukkan sensitiviti dan spesifisiti diagnostik yang memuaskan. Ujian LFD ini 
berpotensi digunakan seiring dengan ujian pengesanan antibodi untuk diagnosis 
pesakit HCD dan susulan selepas rawatan. 
 
 
xxiv 
 
DEVELOPMENT AND EVALUATION OF AN ANTIGEN DETECTION 
TEST FOR HYDATID CYST DISEASE 
 
 
ABSTRACT 
 
Hydatid cyst disease (HCD) is a zoonotic parasitic disease which can infect 
both humans and animals. Imaging and antibody detection tests have been used to 
diagnose HCD, the former cannot differentiate between hydatid cyst and other 
pathologies; while the latter may not be able to differentiate between past and present 
infections, and may also not be suitable for evaluating treatment efficacy. In this 
regard, antigen detection tests may be able to assist in addressing the above issues. 
Previously it has been reported that hydatid cyst antigens can be detected in HCD 
patients using various assays. However the reported results were not satisfactory, 
with variable diagnostic sensitivities (25% - 83%). Therefore, this study was aimed 
at developing an antigen detection test for HCD. A panel of samples comprising 
serum from HCD patients (n=35), healthy individuals (n=38) and patients with other 
parasitic diseases (n=13) were used. Three types of E. granulosus antigens were 
prepared i.e. hydatid cyst fluid (HCF), native antigen B (nAgB) and recombinant 
antigen B (rAgB). Polyclonal antibodies against each of the antigens were produced 
in rabbits, followed by purification of their IgG fractions. Next, a portion of the 
purified IgGs were labelled with horseradish peroxidase (HRP). Using the three 
types of IgGs and three types of HRP-conjugated antibodies, various ELISA 
sandwich combinations were tested. The best ELISA combination was further 
optimized and evaluated using the panel of serum samples. Another portion of the 
purified IgGs were conjugated to colloidal gold nanoparticles for development of 
lateral flow dipstick (LFD). The dipsticks were dotted with three different IgGs, and 
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LFD assay using various combinations of capture and detector antibodies were 
tested. The best LFD assay combination was then further optimized and evaluated, 
both qualitatively (visually) and quantitatively using a lateral flow reader. Results 
showed that ELISA combination that used anti-HCF-IgG as the capture antibody, 
and anti-nAgB-IgG-HRP as the detector antibody exhibited the best signal among all 
other combinations. However, further testing revealed low diagnostic value of the 
assay. Meanwhile LFD assay using dipstick dotted with anti-nAgB-IgG and gold 
conjugated anti-HCF-IgG was the best LFD assay combination. On further testing, 
the LFD assay demonstrated 77.14% diagnostic sensitivity and 82.35% diagnostic 
specificity. The AUC of the LFD assay was determined to be 0.849, which indicated 
good diagnostic accuracy. In conclusion, the antigen detection LFD assay showed 
satisfactory diagnostic sensitivity and specificity. It is envisaged that the LFD assay 
is useful to be used in tandem with an antibody detection test for HCD patient 
diagnosis and post-treatment follow-up. 
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CHAPTER 1 : INTRODUCTION 
 
1.1       Overview of hydatid cyst disease (HCD) 
 HCD which is also known as cystic echinococcosis, unilocular 
echinococcosis or cystic hydatid disease is a zoonotic disease and it is caused by the 
metacestode (larval stage) of the tapeworm Echinococcus granulosus which can 
infect human, livestock and wildlife. Adult cestodes live in the small intestines of 
dogs or other canids as their definitive hosts and shed their ova through their faeces. 
Sheep, goat, cow and other herbivores act as their intermediate hosts and get infected 
by ingestion of water or plants which are contaminated with ova of the adult worm. 
Humans are accidental intermediate hosts and become infected by ingestion of E. 
granulosus ova. After peroral infection of humans, the ova that comes in contact with 
gastrointestinal enzymes will hatch into oncospheres and they migrate to different 
organs mostly liver and lungs through the vascular or lymphatic systems. Then, the 
oncospheres will develop into metacestodes and form hydatid cysts. The hydatid cyst 
gradually increases in size and is filled with hydatid fluid and protoscoleces. HCD is 
a chronic and complex disease (Moro and Schantz, 2009). Morbidity and mortality of 
HCD are due to failure or dysfunction of affected organs, rupture of the hydatid cyst, 
sepsis and anaphylactic shock (Thompson, 2017).  
HCD is distributed worldwide with an emerging or re-emerging status with 
reported incidences from South America, East Asia, Middle East, North Africa, and 
Mediterranean countries in mostly undeveloped areas (Romig, 2003). However, its 
re-emerging status with noticeable economic loss has also been reported in 
developed countries (Rojo-Vazquez et al., 2011). HCD causes considerable loss of 
disability adjusted life years (DALYs) in many under developed areas and has a big 
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impact on the economy because of complications in treatment and resultant 
disabilities (Budke et al., 2006). Recently, HCD was included in a diverse group 
known as “neglected tropical diseases (NTDs)” by the World Health Organization 
(WHO). The NTDs is a group of communicable diseases that  prevails in tropical and 
subtropical regions with prevalence among the most impoverished areas and  have 
not been given enough importance at the national or international levels (WHO, 
2010).  
The diagnosis of HCD is based on the clinical signs followed by imaging and 
serodiagnosis. Clinical symptoms such as abdominal pain and vomiting is non-
specific and imaging of suspected organs cannot differentiate between hydatid cyst, 
abscess or tumour (Zhang et al., 2003a). Thus, imaging along with serological test 
are used to confirm HCD. However, serodiagnosis are probably more useful in early 
diagnosis and post-treatment follow-up of the disease (Craig et al., 2007a).  
Previously, many serological tests based on the detection of specific antibodies 
or antigens have been reported for diagnosis of HCD (Sarkari and Rezaei, 2015). 
There are various serological tests available for detection of antibodies against HCD 
in the format of enzyme-linked immunosorbent assay (ELISA), indirect 
immunofluorescence antibody test (IFAT), immunoelectrophoresis (IEP), and 
immunoblotting (IB) (Zhang et al., 2012b). However these tests have several 
limitations e.g. cross-reaction with other infections, variable sensitivity, inability to 
differentiate between past and present infections as well as to evaluate treatment 
efficacy (Mariconti et al., 2014). In this regard, an antigen detection test may be able 
to assist in addressing the issues stated above (Devi and Parija, 2003b; Sadjjadi et al., 
2009). Currently, commercial tests for diagnosis of HCD are only available in the 
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form of antibody detection and there is no antigen detection kit available in the 
market. 
  
1.2       History of HCD 
Hydatid cysts were well known in ancient times. This kind of cyst was 
mentioned in the Babylonian Talmud when seen in animals which were slaughtered 
in religious ceremonies. Hippocrates and Galen also reported the same condition in 
animals that were butchered for food. Hydatid cysts in humans were described in old 
European medical texts as enlarged glands or bags of mucosa connected to blood 
vessels with rapid growth in size. Francisco Redi in year 1600 proposed the parasitic 
nature of hydatid cyst (Ridley, 2012) and the German clinician, Pierre Simon Pallas 
in 1766, for the first time showed that E. granulosus was linked to the cyst. The first 
valid name, “Hydatigena garnulosa” was given by Batch in 1786 based on 
recognized cysts in sheep from Germany. A few years later in 1801, the genus 
Echinococcus was named by Rudolphi. However, the link between the cyst and the 
metacestode was not yet recognized. Siebold and Küchenmeister in 1853 
demonstrated that hydatid cysts from sheep are the origin of adult tapeworms in dogs 
and shortly thereafter in 1863 Bernhard Naunyn showed adult tapeworms developed 
in dogs which were fed with human hydatid cysts (Cox, 2002; Tappe et al., 2010).  
Although this disease was discovered in the olden times, only  in the present 
century was significant progress made in biology, immunology, diagnosis, treatment 
and epidemiology of HCD (Eckert and Thompson, 2017). In Iran, E. granulosus was 
identified in stray dogs in Tehran for the first time by Makarehchian and Janbakhsh 
in 1956 and two decades later Mobedi and Sadeghian reported Echinococcus 
multilocularis in red foxes in the northeast part of Iran (Ghafarifar, 2010). To the 
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best of our knowledge, the history of HCD in Malaysia has not been documented and 
Malaysia is a non-endemic area for HCD with just a few cases of human HCD 
reported. These cases were imported from neighbouring or other countries which are 
endemic for HCD. The first and latest documented case of HCD in Malaysia were 
reported by Kutty et al. (1970) and Suria Hayati et al. (2015) respectively. 
 
1.3       Classification of the genus Echinococcus 
Echinococcus is a small endoparasitic flatworm belonging to the Kingdom 
Animalia. This parasite is classified under Phylum Platyhelminthes (flatworms) in 
the Class Cestoda (tapeworm) because of its flat ribbon-like body, with anterior 
scolex and posterior tape made of segments. The adult worm do not have alimentary 
canal and body cavity and a syncytial tegument cover the outer body. The parasite is 
a true tapeworm in the subclass Eucestoda because its elongated body consist of a 
linear set of proglottids (male and female reproductive organs) and hermaphroditic 
characteristics. All the parasitic tapeworms which can infect humans are classified in 
the Order Cyclophyllidea because they have indirect life cycles involving larval form 
in intermediate host and are transmitted to the definitive host by carnivorism where 
they develop into adult worms with four suckers on the scolex. Echinococcus is 
placed in the Taeniidae family due to its operculated eggs with two covering, 
unpaired genitalia in each proglottid with irregularly alternating lateral genital pores. 
However, Echinococcus has only up to six proglottids compared with other members 
of this family such as Taenia which may have more than a thousand proglottids 
(Thompson and McManus, 2001; Thompson, 2017). Table 1.1 shows the full 
scientific classification of the genus Echinococcus. 
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Table 1.1 The scientific classification of the genus Echinococcus (Thompson 
and McManus, 2001). 
Domain: Eucaryota 
Kingdom: Animalia 
Phylum: Platyhelminthes 
Class: Cestoda 
Subclass: Eucestoda 
Order: Cyclophyllidea 
Family: Taeniidae 
Genus: Echinococcus 
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1.4       Species of the genus Echinococcus 
In the past, there was a debate on whether echinococcosis (hydatidosis) might 
be caused by one or more species. Meanwhile more species were described and 
identified based on the differences in adult worm morphology such as rostellar hook 
shape, number of proglottids and position of the genital pore (Romig et al., 2015). 
However, some of these newly identified species were not considered valid and 
separate species. Thus far, nine species were accepted as valid species of 
Echinococcus. However, just four of them are common and have high importance 
(Nakao et al., 2013). Table 1.2 shows the valid species in the genus Echinococcus. 
The four most common species of the genus Echinococcus with valid taxonomy and 
well recognized are namely: Echinococcus granulosus (Batsch, 1786), Echinococcus 
multilocularis (Leuckart, 1863), Echinococcus oligarthrus (Diesing, 1863) and 
Echinococcus vogeli (Rausch and Bernstein, 1972). These four species have distinct 
morphology in both their larval and adult stages (Thompson and McManus, 2001). E. 
granulosus and E. multilocularis are the most important species as they cause human 
HCD and human alveolar hydatid disease respectively. Infection with these two 
species is severe and leads to economic loss. Figure 1.1 displays the morphology 
differences of adult Echinococcus species.  
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Table 1.2 A list of valid species in the genus Echinococcus (Nakao et al., 2013). 
Species Synonym and first identified Distribution 
Definitive 
hosts ** 
Intermediate 
hosts ** 
Hydatid 
features 
Human 
infection 
Echinococcus 
granulosus 
Hydatigena 
granulosa 
(Batsch, 1786)  
Worldwide Dog Sheep, goat and cattle Unilocular Common 
Echinococcus 
multilocularis 
Taenia 
multilocularis 
(Leukart, 1863)  
Holarctic Red fox and arctic fox 
Arvicoline 
rodents Alveolar Common 
Echinococcus 
oligarthrus 
Taenia 
oligarthra 
(Diesing, 1863) 
Neotropical Wild felids Agoutis Unilocular Uncommon
Echinococcus 
vogeli – Neotropical Bush dog Paca Polycystic Uncommon
Echinococcus 
ortleppi – Worldwide* Dog Cattle Unilocular Uncommon
Echinococcus 
Canadensis*** 
Echinococcus 
granulosus 
Canadensis 
(Webster and 
Cameron, 1961) 
Worldwide* 
/Northern 
arctic and 
boreal 
Dog/Wolf 
Pig, camel, 
cattle, goat 
and sheep/ 
Moose, 
reindeer and 
wapiti 
Unilocular Uncommon
Echinococcus 
equinus 
Echinococcus 
granulosus 
equinus 
(Williams and 
Sweatman, 1963)
Worldwide* Dog Horse Unilocular Unknown 
Echinococcus 
shiquicus – 
Tibetan 
plateau Tibetan fox Pika Unilocular Unknown 
Echinococcus 
felidis – Africa Lion Unknown Unknown Unknown 
* Sporadic distribution 
** Only the most significant hosts are listed 
*** Three different genotypes with different distribution and hosts, refer to the source. 
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Figure 1.1  Comparative general morphology of the most important adult 
Echinococcus species (Thompson and McManus, 2001). 
A: Echinococcus vogeli  
  B: Echinococcus granulosus   
  C: Echinococcus oligarthrus 
  D: Echinococcus multilocularis 
  ← and →:  Genital pore 
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1.5       Morphology and biology of E. granulosus 
1.5.1 Adult stage 
Adult E. granulosus measures approximately 2 to 7 millimeters (mm) in 
length and is one of the smallest endoparasite worms among all tapeworms. The 
worm is composed of the scolex (head), narrow neck and body. The head or 
spherical scolex is equipped with specialized attaching tools consisting of four 
muscular suckers and two circular rows of hooks (22-40 µm), one row with big 
hooks and another row with small hooks which all placed on the rostellum. The 
narrow neck is a regenerative part and separates the scolex from the rest of the body. 
The body or storbila is segmented which consists of three to four proglottids 
(reproductive units) and in rare cases up to six proglottids (Thompson and McManus, 
2001). 
The first segment is not mature and no genital organ will develop inside. The 
penultimate segment is sexually mature and both male and female organs will 
develop. In the male organ, usually around 50 follicular testes are scattered in the 
mature proglottid. Each testis links to a single vas deferens and all vas deferens 
become united to form one main vas deferens which connects to the male copulatory 
organ called cirrus. The female organ is composed of the ovary, ootype, coiled uterus 
and vitellaria in the cirrus sac which opens to the lateral genital pore. E. granulosus 
is hermaphroditic and is capable of both self or cross fertilization (Roberts et al., 
2013; Mandal, 2015) .  
The last proglottid is gravid and measures approximately 2.0 mm x 1.0 mm 
with a uterus filled with approximately 5000 eggs. The eggs that are released from 
the proglottid are oval shaped measuring 30-37 µm in diameter and each egg 
contains a single hexacanth oncosphere (embryo). Under the light microscope, the 
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eggs of E. granulosus are morphologically indistinguishable from the eggs of Taenia 
species.  The eggs are covered with a thick and resistant outer layer which is capable 
of surviving in the environment for long periods (6-12 months) and are infective to 
humans and animals (Thompson, 2017). The figure 1.2 displays the body structure 
and organs of an adult E. granulosus. 
 This tapeworm has no digestive tract and it absorbs food through the outer 
body layer (tegument) when in contact with nutrients in the intestine of their 
definitive host. The microtriches on the tegument increases the surface area for food 
absorption. The nervous system of an adult worm consists of five pairs of 
longitudinal nerves. The motor nerves is responsible for the contraction of the 
suckers on the scolex for the  purpose of attachment to the intestine wall of the host 
(Flisser and Craig, 2010). The excretion system consists of Flame cells and canals. 
The Flame cells are found in all endoparasitic tapeworms and they maintain the 
organ’s osmotic balance by excreting wastes through the ventrolateral and 
dorsolateral canals. There are canals on each side of the worm’s body along the 
storbila which  conduct wastes to the external environment (Roberts et al., 2009). 
The key definitive host of adult E. granulosus are  domestic dogs, but it can 
also  be found in other canids such as wolves, golden jackals and red foxes (Rokni, 
2008; Craig et al., 2015). They acquire infection by ingesting the infected organs of 
intermediate host (herbivores or omnivores) with fertile hydatid cysts containing 
viable protoscoleces. After ingestion, the apical region of scolex invaginate within 
the basal region of protoscolex tegument to protect the suckers, hooks and rostellum 
until it is stimulated to evaginate by external factors i.e. proteolytic enzymes (pepsin 
and pancreatin), host's bile salt and the microtopography of the intestine.  Following 
evagination, the protoscolex is very active and it penetrates deeply into the mucosal 
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surface between the villi and the crypts of Lieberkuhn. The protoscolex then 
develops into the adult worm in 34-58 days. Sexual maturity starts with egg 
production in the proglottid and release of gravid proglottid into the small intestine 
which is excreted with the faeces. The infected definitive host carries adult E. 
granulosus in their intestines (Lewall, 1998; Thompson, 2017). Figure 1.3 shows the 
development stages of E. granulosus from protoscolex to an adult worm. 
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Figure 1.2 Adult worm of E. granulosus. 
  A: Schematic diagram of body structure and organs 
   (nscu.edu, 2017). 
  B: Light microscopic (100X) image of an adult worm 
   (www.k-state.edu, 2017). 
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Figure 1.3 Stages of development of E. granulosus from protoscolex to adult 
mature worm (Thompson, 2017).  
B: band, CC: calcareous corpuscles, CS: cirrus sac, E: embryonated 
eggs, EC: excretory canal, FD: female reproductive ducts, GP: genital 
pore, GR: genital rudiment, H: hooks, O: ovary, R: rostellum,                   
S: suckers, Sc: scolex, Sg: segment, SR: seminal receptacle,                    
Tr: rudimentary testes, T: testes, U: uterus V: vagina, VD: vas 
deferens, VG: vitelline gland, Z: zygotes. 
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1.5.2 Larva stage (metacestode) 
 The metacestode of E. granulosus develops into unilocular cyst (hydatid cyst) 
in their intermediate hosts. The cyst is spherical in shape, filled with clear fluid 
(hydatid fluid) and contains complex structures of the E. granulosus. The size of the 
cyst may vary from 1 to 15 centimeter (cm) in diameter, however larger cyst may 
also be observed (Eckert and Deplazes, 2004; Moro and Schantz, 2009). Figures 1.4 
and 1.5 show the pictures of hydatid cysts in the liver and an isolated unilocular 
hydatid cyst respectively. The hydatid cyst comprises three layers: 1.Adventitial 
layer, 2.Laminar layer and 3.Germinal layer. 
 
1.5.2(a) Adventitial layer (pericyst or pseudocyst) 
 The adventitial layer or host fibrous layer is produced by host tissue and 
surrounds the hydatid cyst. This layer comprises collagen and fibroblast cells. The 
hydatid cyst  receives nutrients through blood vessels in this layer by diffusion 
(Vanek, 1980).  
 
1.5.2(b) Laminar layer (ectocyst) 
 The laminar layer or laminated layer is formed as a result of the host’s 
cellular inflammatory reaction which surrounds the viable hydatid cyst (Thompson, 
2017). This layer is acellular, tough and elastic and varies in thickness. The laminar 
layer is formed around the germinal layer between 2 to 4 weeks after peroral 
infection of the intermediate host with E. granulosus eggs and oncosphere liberation 
(Zhang et al., 2003a). 
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Figure 1.4 Hydatid cysts in liver (A) and lung (B) of sheep infected with E. 
granulosus (Almalki et al., 2017). 
 
 
Figure 1.5 Spherical and unilocular hydatid cyst of E. granulosus.  
(southhampton.ac.uk, 2017). 
 
Hydatid cyst                      B 
Hydatid cyst            A 
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1.5.2(c) Germinal layer (endocyst) 
 This layer is a single layer of cells lining the inner area of the cyst. The 
structure of the germinal layer or germinal epithelium is similar to the outer body 
layer (tegument) of the adult worm. This layer is the true wall of the cyst with a 
thickness of 10-20 µm. This layer comprises several cell types i.e. muscle cells, 
glycogen storing cells, tegumental cells and undifferentiated cells. The 
undifferentiated cells are the proliferative layer which produces the laminated layer, 
brood capsules and scoleces. The brood capsule is formed as a small bud and 
proliferates toward the cyst cavity (Galindo et al., 2008; Thompson, 2017).   
 
1.5.2(d) Brood capsules    
 The brood capsules are small vesicles or small secondary cysts which grow 
large and asexual buds form within their lumen from the germinal layer to produce 
many protoscoleces (Moro and Schantz, 2009; Siracusano et al., 2009). 
Protoscoleces develop asynchronously and at the final stage of development, the 
hooks are positioned on the invaginated rostellum (Thompson, 2017). The small 
vesicles are stalked to the germinal layer of the larger mother cyst and grow big to 
form secondary cysts (daughter cysts) or may release the protoscoleces into the 
hydatid fluid by rupturing (Garcia et al., 2011). Figures 1.6 shows a cross-section of 
a hydatid cyst and figure 1.7 shows E. granulosus protoscolex. 
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Figure 1.6 Diagrammatic representation of a cross section of unilocular E. 
granulosus hydatid cyst (Diaz et al., 2011). 
 a: Small vesicle is formed from inner layer of the germinal layer 
  b: Small vesicle vacuolated and performed a cavity inside. 
  c: Protoscoleces are initially formed in small vesicle 
d: Fully developed protoscoleces (with hooks) are formed within 
vesicle 
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Figure 1.7 E. granulosus protoscolex , (A) Diagram of invaginated protoscolex 
(left) and evaginated protoscolex (right) (www.isradiology.org, 2017); 
(B) light microscopic (x200) picture of hydatid sands (atlas.or.kr, 
2017).   
 
 
 
A 
B 
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1.5.2(e) Protoscolex 
 Protoscolex become apparent from the inner wall of brood capsule. The 
exact time of the development of protoscolex within the hydatid cyst in human is not 
clear, but it is estimated to be more than 10 months after infection. Usually 
protoscoleces are observed in cysts with a size of 5 to 20 mm in diameter. Also, 
some proportion of cysts may remain sterile as they do not produce protoscoleces 
(Eckert and Deplazes, 2004). A fully developed protoscolex measures about 3 mm in 
length and it is similar to an adult scolex. It has many hooks in two parallel rows on 
the rostellum (Muller and Wakelin, 2002). After digestion of hydatid cyst containing 
protoscoleces by their definitive hosts, the invaginated protoscolex evaginates in the 
gastro-intestine tract of the definitive host and attaches to the intestine wall using 
hooks and suckers on the rostellum and scolex. Finally, it develops into an adult 
worm. If there is hydatid cyst spillage or ruptures in the intermediate host, the 
released protoscoleces may develop new cysts in the surrounding tissues. The 
protoscoleces with other components in the hydatid cyst including hooks, calcareous 
corpuscles and brood capsules form a white sediment called hydatid sand at the 
bottom of the hydatid cyst (Eckert and Deplazes, 2004; Czermak et al., 2008).  
 
1.5.2(f) Calcareous corpuscle  
 Calcareous corpuscle (CC) is the main component (14% of dried weight) of 
E. granulosus protoscoleces. The CCs are oval in shape and they measure between 2 
µm to 15 µm in diameter (McManus and Bryant, 1995). The exact function of CCs is 
not completely clear. But it is thought that CC is a ready source of calcium carbonate 
and it is responsible for lipid metabolism, osmotic balance and tissue repair. (Li et 
al., 2004). 
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1.5.2(g) Hydatid cyst fluid 
 Hydatid fluid is a clear or clear yellow fluid with pH of 6.7 and specific 
gravity of about 1.0. This fluid is secreted by germinal layer of hydatid cyst and it 
provides nutritional requirements for larval growth and development. This fluid 
contains inorganic material, biochemical metabolites and proteins (Juyi et al., 2013). 
The pressure of hydatid fluid in the cyst is about 0.5 psi of water which keeps the 
endocyst in close contact with the pericyst (Palmer and Reeder, 2001).   
 
1.6       Life cycle of E. granulosus 
 E. granulosus requires two hosts which belong to the bovid and canid 
families, in order to complete life cycle. A carnivorous animal as a definitive host 
which harbours the adult worm in the small intestine and produce ova/eggs (sexual 
phase), and a herbivorous animal as an intermediate host in which the metacestode 
develops into cyst containing protoscoleces in the viscera (asexual phase). There are 
two type of life cycle for E. granulosus called the natural cycle and sylvatic cycle. In 
the natural cycle or domestic cycle, domestic dogs act as the definitive host and 
domestic herbivores or omnivores such as sheep, goat, cow, camel and pig are the 
intermediate host. The sylvatic cycle or wild cycle involves wild carnivores such as 
wolf as the definitive host and wild ungulates like moose and reindeer as the 
intermediate host. The adult E. granulosus releases the gravid proglottids filled with 
eggs into the intestine of the definitive host and the definitive host sheds the eggs 
with their faeces to the environment. The intermediate hosts become infected by 
ingestion of water or plants which are contaminated with the eggs. Humans get 
infected by accidental ingestion of E. granulosus eggs and are dead-end host (Eckert 
et al., 2001; Eckert and Deplazes, 2004). 
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 After oral uptake of E. granulosus egg by a human, the fully embryonated 
and infective egg hatches in the stomach and small intestine. The oncosphere is 
liberated from the oncospheral membrane presumably after being activated by bile 
salts. The free oncosphere migrates toward the intestinal wall and penetrates deeply 
into the tips of the intestinal villi using both hooks and secretion before reaching the 
vascular and lymphatic system. The oncosphere migrates to the internal organs 
through the vascular system and localizes. Once the oncosphere localizes in an 
organ, it develops into the metacestode and forms a cyst. The cyst is gradually filled 
with hydatid fluid and protoscoleces (Thompson, 2017). In an infected human, 
hydatid cyst may be observed in one or more organs mostly in the liver and lungs, 
and in rare cases the brain, kidneys and bone (Brunetti et al., 2011). The size of 
hydatid cyst measures about 1 mm in diameter at 1 month post-infection and after 5 
months it grows to 10-55 mm. The life cycle of E. granulosus will be completed 
when the definitive host ingest infected organs and viscera of the intermediate host 
containing hydatid cyst with viable protoscoleces. The protoscoleces evaginate in the 
stomach of the definitive hosts and attach to the wall of the small intestine using the 
suckers and hooks on the scolex where they develop into mature adult worms within 
seven weeks (Muller and Wakelin, 2002).  The figure 1.8 illustrates the life cycle of 
E. granulosus. 
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Figure 1.8 Life cycle of E. granulosus (Levinson, 2016). 
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1.7       Epidemiology of E. granulosus 
The distribution of E. granulosus globally is generally related to animal 
husbandry (domestic life cycle). There are only a few places in North America and 
Eurasia where the sylvatic life cycle (wild life cycle) is established (Thompson, 
2008). The specific roles of various host species in the cycle of the disease, might be 
notably different between endemic regions. Domestic and sylvatic life cycles could 
co-exist or overlap in many endemic areas (Eckert and Deplazes, 2004). Using 
molecular biology techniques, McManus and Thompson (2003) described ten 
distinct strains (genotypes) of E. granulosus namely G1 to G10. They used 
mitochondrial DNA sequences to identify genotypes and it appears that each 
genotype has adopted a particular life cycle pattern which involves specific hosts. 
These ten genotypes include two sheep strains (G1 and G2), two cattle strains (G3 
and G5), one horse strain (G4), one camelid strain (G6), one pig strain (G7), one 
cervid strain (G8) ,one Poland swine strain (G9) and one Eurasia reindeer strain 
(G10). The G1 strain is the common sheep-dog strain which is the cause of most 
human infections. This strain is geographically distributed specifically in North 
Africa. The G2 strain is the Tasmanian sheep strain which is distributed in Tasmania 
and Argentina. The emergence of this strain in some endemic European countries 
(Italy, Spain, Portugal, France and Bulgaria) have been reported recently. The G3 
and G5 strains (cattle strains) are both distributed in Asia, but G5 (like the G4 horse 
strain) is also endemic in Europe. The G8 strain is maintained in the sylvatic cycle in 
North America and Eurasia where wolves or dogs act as the definitive host and 
reindeer and moose act as the intermediate host. Human infection with this strain is 
rare. In the new classification, the old classified genotypes G1 to G5 were 
reclassified as follows: G1 to G3 into E. granulosus sensu strict; G4 into E. equines 
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and G5 into E. ortleppi (McManus and Thompson, 2003; Siracusano et al., 2012b; 
Romig et al., 2015).  
With  respect to the human infections, the G1 strain (sheep strain) and G5 
strain (bovid strain) are the most important strains (Stojkovic et al., 2014). In Iran the 
presence of the G1, G3 and G6 genotypes have been reported by Sharafi et al. 
(2014).  
 
1.7.1 Risk of hydatid cyst infection in human 
 Humans become infected by peroral ingestion of E. granulosus eggs which 
infected dogs or other canids (definitive host) passed with their faeces into the 
environment. The identification of risk factors for infection in humans is complicated 
because of the long latent period between the initial infection, and appearance of 
clinical symptoms and diagnosis of the disease. In addition, humans and dogs are 
capable of widespread movements. The infection can be transmitted to humans by 
direct and indirect ways. The direct infection or hand-to-mouth route happens 
particularly where there is intimate contact of humans with dogs. The eggs attach to 
the hairs around the anus of infected dogs and can also be found attached to the paws 
and muzzle which may transfer to humans who touch the dog.  Indirect transfer 
happens via handling or consuming water or food such as vegetables, salad and raw 
meat contaminated with E. granulosus eggs. The indirect transmission can also 
happen through intermediaries such as flies or other arthropods (Moro and Schantz, 
2009). The prenatal transfer of the disease has still not been reported (Conn, 1994). 
 Humans of all ages are susceptible to HCD. The disease has been reported in 
children younger than 1 year old as well as adults older than 75 years old and there is 
no differences in disease prevalence between males and females. About 60% of the 
